Loading
journalsJournal
Endocrine-related cancer
Endocrine-Related Cancer is the Society for Endocrinology's cancer journal, covering endocrine tumours and hormone-dependent cancers such as breast, prostate, thyroid and neuroendocrine tumours. Endocrinologists and cancer biologists read it.
Also called: Endocr Relat CancerERCEndocrine-Related Cancer
Overview
Endocrine-Related Cancer provides an international forum for original articles describing basic laboratory, translational and clinical investigations of human health and disease focusing on endocrine neoplasias and hormone-dependent cancers, together with authoritative review articles on these topics. The journal has continuous online publication in monthly issues. It is published by Bioscientifica, the publishing arm of the Society for Endocrinology, and NLM records that it was published for the Society for Endocrinology by the Journal of Endocrinology Ltd from 1994 and by Bioscientifica in Bristol from January 2011, as the successor to Reviews on Endocrine-Related Cancer, and is also known as ERC. NLM lists it as quarterly in its record and indexed in MEDLINE and PubMed. The journal site has an open access policy and publication charges page, but the overall access model was not readable from the pages consulted, so none is recorded. Not listed in DOAJ.
Publisher
Bioscientifica · Society for Endocrinology
Scope
endocrine oncology
Founded
1994
ISSN
1351-0088
observational2015changed practice277 citations
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
Grade 3 neuroendocrine tumours are treated like aggressive grade 2 tumours (somatostatin analogues, capecitabine-temozolomide, radioligand therapy) rather than with small-cell regimens.
review2005977 citations
BRAF mutation in thyroid cancer
One of the most cited reviews Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Martyn E. Caplin
Professor of Gastroenterology and Neuroendocrine Tumours, Royal Free Hospital and UCL
Neuroendocrine tumoursSomatostatin analoguesGastroenterology
Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.
Steven K. Libutti
Director, Rutgers Cancer Institute of New Jersey
Surgical oncologyEndocrine and neuroendocrine tumoursCancer centre leadership
Surgeon who directs Rutgers Cancer Institute of New Jersey, the state's NCI-designated comprehensive cancer centre.
Takayuki Ueno
Breast surgical oncologist, Cancer Institute Hospital of JFCR
Breast surgeryNeoadjuvant therapyTranslational research
Takayuki Ueno is a breast surgeon whose translational work links tumour biology to neoadjuvant response.
observationalEndocrine-related cancer 2015changed practice277 citations
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
Grade 3 neuroendocrine tumours are treated like aggressive grade 2 tumours (somatostatin analogues, capecitabine-temozolomide, radioligand therapy) rather than with small-cell regimens.
reviewEndocrine-related cancer 2005977 citations
BRAF mutation in thyroid cancer
One of the most cited reviews Europe PMC returns for BRAF in Thyroid cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Similar pages
- InstitutionRoyal Free Hospital, Royal Free London NHS Foundation Trust
Shares Martyn E. Caplin, Neuroendocrine tumours.
- IdeaBRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer
- JournalChinese clinical oncology
Shares Takayuki Ueno, PubMed & Europe PMC.
- TargetEPHB2
Shares Thyroid cancer, Neuroendocrine tumours, Prostate cancer.
- TrialCLARINET
Shares Martyn E. Caplin, Neuroendocrine tumours.
- TargetEPHA3
Shares Thyroid cancer, Neuroendocrine tumours, Prostate cancer.
- JournalEuropean thyroid journal
Shares Thyroid cancer, PubMed & Europe PMC.
- TargetCDKN1B
Shares Thyroid cancer, Neuroendocrine tumours, Prostate cancer.